THR-317 for the treatment of diabetic macular edema was found to be safe and well tolerated in a phase 1/2 study, ThromboGenics announced.
The single-masked, multicenter THR-001 study evaluated THR-317, a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor, for safety and efficacy at two dose levels, 4 mg and 8 mg, according to a press release.
Forty-nine anti-VEGF-naive subjects and suboptimal anti-VEGF responders were enrolled. These results pertain to the 40 patients who were treatment-naive.
No dose-limiting toxicities or
Uncategorized